Big Data, Transparency and Accountability
We crave clinical and scientific data, yet we grieve the performance-based data increasingly directed toward us.
All articles by Robert Uzzo, MD, MBA, FACS
Personalized Medicine in 2014
The term “personalized medicine” remains an overused promise to apply specific treatment plans.
Genetic Risk and PCa Treatment: A New Era Dawning
For men at risk of developing prostate cancer (PCa), prophylactic prostatectomy seems almost irrational for several reasons
Physicians: Managers of Risk
Physicians are more often defined by their ability to diagnose, treat, and research a disease than their willingness to manage its spectrum of risk.
Metabolic Abnormalities Following Urinary Diversion
Radical cystectomy with urinary diversion including neobladder remains the standard of care for muscle-invasive bladder cancer.
Obesity and Prostate Cancer Risk
Although data suggest that cancer rates are also higher in obese patients, the associations are largely based on observational/population studies.
CT and Stones: Can We Do Better with Less?
Cross-sectional imaging now substitutes for physical diagnosis in most emergency rooms.
RCC or Dialysis: Risk Stratification and Assessment
Risk-stratifying patients requires a urologist’s understanding of the natural history of disease, competing risks, and morbidities of interventions.
Prostate Cancer Screening: Moving Beyond PSA
More than 1 million prostate biopsies are performed annually in the United States, predominantly driven by elevations in PSA.
ACOs and Productivity Metrics in Medicine
Individuals, businesses and nations grapple with how to measure success. Are similar productivity measures warranted in medicine?
- Loading...
Loading...
Loading... 
Loading...